ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ:ADMP) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07
|
Submission of Matters to a Vote of Security Holders. |
The Annual Meeting of Stockholders of Adamis Pharmaceuticals
Corporation (the Company) was held on June 7, 2017, at the
Companys headquarters at 11682 El Camino Real, Suite 300, San
Diego, California 92130 at 10:00 a.m. local time. The following
proposals were submitted to and approved by the stockholders at
the meeting:
1.
Election of the five nominees to the board of directors:
| Votes For | Votes Withheld | Votes Abstaining | Broker Non-Votes | |
| Dennis J. Carlo, Ph.D. | 4,253,446 | 654,410 | 10,563,076 | |
| William C. Denby, III | 4,439,051 | 468,805 | 10,563,076 | |
| David J. Marguglio | 4,235,294 | 672,562 | 10,563,076 | |
| Robert B. Rothermel | 4,437,789 | 470,067 | 10,563,076 | |
| Richard C. Williams | 4,361,566 | 546,290 | 10,563,076 |
2.
Approval, on a nonbinding advisory basis, of the compensation of
the Companys named executive officers:
| Votes For | Votes Against | Votes Abstaining | Broker Non-Votes |
| 3,167,659 | 1,619,787 | 120,410 | 10,563,076 |
3.
Ratification of the selection of Mayer Hoffman McCann PC as
independent registered public accounting firm for the year ending
December 31, 2017:
| Votes For | Votes Against | Votes Abstaining | |
| 14,910,804 | 457,160 | 102,968 |
About ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ:ADMP)
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company’s lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.
